Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns.

Autor: Daoran Lu¹, Fangzhou Dou¹, Jianjun Gao¹ gaojj@qdu.edu.cn

Publikováno v: Drug Discoveries & Therapeutics. Dec2023, Vol. 17 Issue 6, p440-444. 5p.

Are antibodies directed against amyloid-β (Aβ) oligomers the last call for the Aβ hypothesis of Alzheimer's disease?

Autor: Panza F; Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, & Sense Organs, University of Bari Aldo Moro, Bari, Italy.; Department of ClinicalResearch in Neurology, Center for Neurodegenerative Diseases and the AgingBrain, University of Bari 'Aldo Moro', 'Pia Fondazione Cardinale G. Panico', Tricase, Lecce, Italy.; Geriatric Unit, Fondazione IRCCS 'Casa Sollievo della Sofferenza', SanGiovanni Rotondo, Foggia, Italy., Lozupone M; Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, & Sense Organs, University of Bari Aldo Moro, Bari, Italy., Dibello V; Interdisciplinary Department of Medicine (DIM), Section of Dentistry, University of Bari Aldo Moro, Bari, Italy., Greco A; Geriatric Unit, Fondazione IRCCS 'Casa Sollievo della Sofferenza', SanGiovanni Rotondo, Foggia, Italy., Daniele A; Institute of Neurology, Catholic University of Sacred Heart, Rome, Italy.; Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy., Seripa D; Geriatric Unit, Fondazione IRCCS 'Casa Sollievo della Sofferenza', SanGiovanni Rotondo, Foggia, Italy., Logroscino G; Neurodegenerative Disease Unit, Department of Basic Medicine, Neuroscience, & Sense Organs, University of Bari Aldo Moro, Bari, Italy.; Department of ClinicalResearch in Neurology, Center for Neurodegenerative Diseases and the AgingBrain, University of Bari 'Aldo Moro', 'Pia Fondazione Cardinale G. Panico', Tricase, Lecce, Italy., Imbimbo BP; Department of Researchand Development, Chiesi Farmaceutici, Parma, Italy.

Publikováno v: Immunotherapy [Immunotherapy] 2019 Jan; Vol. 11 (1), pp. 3-6.

The Aβ Hypothesis: Leading Us to Rationally-Designed Therapeutic Strategies for the Treatment or Prevention of Alzheimer Disease

Autor: Todd E. Golde

Publikováno v: Brain Pathol

In recent years the amyloid cascade hypothesis of Alzheimer disease (AD) has been increasingly referred to as the amyloid beta protein (Abeta) cascade hypothesis. This subtle rephrasing reflects the acknowledgment that there is debate within the fiel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::98941c9a8587f6b459db0763360b22cd
https://doi.org/10.1111/j.1750-3639.2005.tb00104.x

The synaptic Aβ hypothesis of Alzheimer disease

Autor: Rudolph E. Tanzi

Publikováno v: Nature Neuroscience. 8:977-979

Aβ peptide is linked to Alzheimer pathology, but its toxic mechanism remains unclear. New work shows that Aβ leads to internalization of NMDA receptors, reducing their availability at synapses. The authors also suggest a molecular mechanism for thi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::24c7af41d42035460e366d9401cd73ae
https://doi.org/10.1038/nn0805-977

Semagacestat Is a Pseudo-Inhibitor of γ-Secretase

Autor: Shinji Tagami, Kanta Yanagida, Takashi S. Kodama, Mako Takami, Naoki Mizuta, Hiroshi Oyama, Kouhei Nishitomi, Yu-wen Chiu, Toru Okamoto, Takeshi Ikeuchi, Gaku Sakaguchi, Takashi Kudo, Yoshiharu Matsuura, Akio Fukumori, Masatoshi Takeda, Yasuo Ihara, Masayasu Okochi

Publikováno v: Cell Reports, Vol 21, Iss 1, Pp 259-273 (2017)

γ-secretase inhibitors (GSI) are drugs developed to decrease amyloid-β peptide (Aβ) production by inhibiting intramembranous cleavage of β-amyloid protein precursor (βAPP). However, a large phase 3 trial of semagacestat, a potential non-transiti

Externí odkaz: https://doaj.org/article/e0c2b7842afc48ba9915c840c0c2dbd5